S&P 500   3,948.72
DOW   32,105.25
QQQ   309.75
Why Wall Street Loves These 3 Penny Stocks
The "King Of Quants" sees 10X potential... (Ad)
3 Leading Dividend Stocks Expected To Grow Earnings
Chewy Stock Is Setting Up For Long-Term Profitable Growth 
The "King Of Quants" sees 10X potential... (Ad)
Closing prices for crude oil, gold and other commodities
Low Volume Bunge Plunge Presents an Opportunity
Urgent Warning (Ad)
KB Home Strong Results Lift Prices
Carvana May Be Able To Reach Profitability This Year
S&P 500   3,948.72
DOW   32,105.25
QQQ   309.75
Why Wall Street Loves These 3 Penny Stocks
The "King Of Quants" sees 10X potential... (Ad)
3 Leading Dividend Stocks Expected To Grow Earnings
Chewy Stock Is Setting Up For Long-Term Profitable Growth 
The "King Of Quants" sees 10X potential... (Ad)
Closing prices for crude oil, gold and other commodities
Low Volume Bunge Plunge Presents an Opportunity
Urgent Warning (Ad)
KB Home Strong Results Lift Prices
Carvana May Be Able To Reach Profitability This Year
S&P 500   3,948.72
DOW   32,105.25
QQQ   309.75
Why Wall Street Loves These 3 Penny Stocks
The "King Of Quants" sees 10X potential... (Ad)
3 Leading Dividend Stocks Expected To Grow Earnings
Chewy Stock Is Setting Up For Long-Term Profitable Growth 
The "King Of Quants" sees 10X potential... (Ad)
Closing prices for crude oil, gold and other commodities
Low Volume Bunge Plunge Presents an Opportunity
Urgent Warning (Ad)
KB Home Strong Results Lift Prices
Carvana May Be Able To Reach Profitability This Year
S&P 500   3,948.72
DOW   32,105.25
QQQ   309.75
Why Wall Street Loves These 3 Penny Stocks
The "King Of Quants" sees 10X potential... (Ad)
3 Leading Dividend Stocks Expected To Grow Earnings
Chewy Stock Is Setting Up For Long-Term Profitable Growth 
The "King Of Quants" sees 10X potential... (Ad)
Closing prices for crude oil, gold and other commodities
Low Volume Bunge Plunge Presents an Opportunity
Urgent Warning (Ad)
KB Home Strong Results Lift Prices
Carvana May Be Able To Reach Profitability This Year
NYSE:TBI

TrueBlue - TBI Stock Forecast, Price & News

$16.96
-0.05 (-0.29%)
(As of 03/23/2023 12:00 AM ET)
Add
Compare
Today's Range
$16.91
$17.27
50-Day Range
$16.69
$20.49
52-Week Range
$15.77
$30.32
Volume
198,678 shs
Average Volume
213,125 shs
Market Capitalization
$556.63 million
P/E Ratio
9.12
Dividend Yield
N/A
Price Target
$20.50

TrueBlue MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
20.9% Upside
$20.50 Price Target
Short Interest
Healthy
2.20% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.79mentions of TrueBlue in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.78 out of 5 stars

Business Services Sector

265th out of 323 stocks

Help Supply Services Industry

15th out of 15 stocks


TBI stock logo

About TrueBlue (NYSE:TBI) Stock

TrueBlue, Inc. engages in the provision of staffing, recruitment process outsourcing and managed service provider solutions. It operates through the following segments: PeopleReady, PeopleManagement and PeopleScout. The PeopleReady segment offers staffing solutions for blue-collar, contingent on-demand and skilled labor to a broad range of industries that include retail, manufacturing, warehousing, logistics, energy, construction, hospitality and others. The PeopleManagement segment supplies contingent labor and outsourced industrial workforce solutions. The PeopleScout segment covers the provision of permanent employee recruitment process outsourcing for its customers for all major industries and jobs. The company was founded by John Ross Coghlan and Glenn Welstad in 1989 and is headquartered in Tacoma, WA.

Receive TBI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TrueBlue and its competitors with MarketBeat's FREE daily newsletter.

TBI Stock News Headlines

TrueBlue (NYSE:TBI) Research Coverage Started at StockNews.com
Anthony Brew Named Chief Diversity Officer of TrueBlue
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
TrueBlue Full Year 2022 Earnings: EPS Misses Expectations
Why TrueBlue, Inc. (NYSE:TBI) Could Be Worth Watching
See More Headlines
Receive TBI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TrueBlue and its competitors with MarketBeat's FREE daily newsletter.

TBI Company Calendar

Last Earnings
2/01/2023
Today
3/23/2023
Next Earnings (Estimated)
4/24/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Help supply services
Sub-Industry
Human Resource & Employment Services
CUSIP
89785X10
Employees
6,500
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$20.50
High Stock Price Forecast
$21.00
Low Stock Price Forecast
$20.00
Forecasted Upside/Downside
+20.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$62.27 million
Pretax Margin
3.26%

Debt

Sales & Book Value

Annual Sales
$2.25 billion
Cash Flow
$3.37 per share
Book Value
$15.17 per share

Miscellaneous

Free Float
32,167,000
Market Cap
$556.63 million
Optionable
Optionable
Beta
1.46

Key Executives

  • Steven C. Cooper
    Chief Executive Officer & Director
  • Taryn R. OwenTaryn R. Owen
    President & Chief Operating Officer
  • Derrek L. GaffordDerrek L. Gafford
    Chief Financial Officer & Executive Vice President
  • Jeffrey S. Dirks
    Chief Information & Technology Officer
  • Garrett R. Ferencz
    Chief Legal Officer, General Counsel & EVP













TBI Stock - Frequently Asked Questions

Should I buy or sell TrueBlue stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for TrueBlue in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" TBI shares.
View TBI analyst ratings
or view top-rated stocks.

What is TrueBlue's stock price forecast for 2023?

2 Wall Street analysts have issued 1 year price targets for TrueBlue's shares. Their TBI share price forecasts range from $20.00 to $21.00. On average, they anticipate the company's share price to reach $20.50 in the next year. This suggests a possible upside of 20.9% from the stock's current price.
View analysts price targets for TBI
or view top-rated stocks among Wall Street analysts.

How have TBI shares performed in 2023?

TrueBlue's stock was trading at $19.58 at the beginning of the year. Since then, TBI shares have decreased by 13.4% and is now trading at $16.96.
View the best growth stocks for 2023 here
.

Are investors shorting TrueBlue?

TrueBlue saw a increase in short interest in the month of February. As of February 15th, there was short interest totaling 677,800 shares, an increase of 22.5% from the January 31st total of 553,300 shares. Based on an average daily volume of 169,000 shares, the days-to-cover ratio is currently 4.0 days. Approximately 2.1% of the company's shares are sold short.
View TrueBlue's Short Interest
.

When is TrueBlue's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, April 24th 2023.
View our TBI earnings forecast
.

How were TrueBlue's earnings last quarter?

TrueBlue, Inc. (NYSE:TBI) posted its quarterly earnings results on Wednesday, February, 1st. The business services provider reported $0.43 EPS for the quarter, topping analysts' consensus estimates of $0.41 by $0.02. The business services provider had revenue of $557.70 million for the quarter, compared to the consensus estimate of $562.93 million. TrueBlue had a trailing twelve-month return on equity of 16.95% and a net margin of 2.76%. The firm's revenue was down 10.3% compared to the same quarter last year. During the same quarter last year, the company earned $0.69 EPS.

What guidance has TrueBlue issued on next quarter's earnings?

TrueBlue updated its first quarter 2023 earnings guidance on Wednesday, February, 1st. The company provided EPS guidance of for the period. The company issued revenue guidance of $455.00 million-$480.00 million, compared to the consensus revenue estimate of $492.18 million.

What is Patrick Beharelle's approval rating as TrueBlue's CEO?

34 employees have rated TrueBlue Chief Executive Officer Patrick Beharelle on Glassdoor.com. Patrick Beharelle has an approval rating of 56% among the company's employees. This puts Patrick Beharelle in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of TrueBlue own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TrueBlue investors own include International Business Machines (IBM), Intel (INTC), NVIDIA (NVDA), Vertex Pharmaceuticals (VRTX), Gilead Sciences (GILD), The Goldman Sachs Group (GS), AT&T (T), Zynga (ZNGA), AbbVie (ABBV) and Amgen (AMGN).

What is TrueBlue's stock symbol?

TrueBlue trades on the New York Stock Exchange (NYSE) under the ticker symbol "TBI."

Who are TrueBlue's major shareholders?

TrueBlue's stock is owned by many different retail and institutional investors. Top institutional shareholders include Dimensional Fund Advisors LP (7.75%), Pzena Investment Management LLC (6.74%), JPMorgan Chase & Co. (2.22%), Charles Schwab Investment Management Inc. (2.18%), Geode Capital Management LLC (1.82%) and Morgan Stanley (1.59%). Insiders that own company stock include A Patrick Beharelle, Carl Schweihs, Colleen B Brown, Derrek Lane Gafford, Garrett Ferencz, Richard Christensen, Steven C Cooper, Taryn R Owen and William C Goings.
View institutional ownership trends
.

How do I buy shares of TrueBlue?

Shares of TBI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is TrueBlue's stock price today?

One share of TBI stock can currently be purchased for approximately $16.96.

How much money does TrueBlue make?

TrueBlue (NYSE:TBI) has a market capitalization of $556.63 million and generates $2.25 billion in revenue each year. The business services provider earns $62.27 million in net income (profit) each year or $1.86 on an earnings per share basis.

How many employees does TrueBlue have?

The company employs 6,500 workers across the globe.

How can I contact TrueBlue?

TrueBlue's mailing address is 1015 A STREET, TACOMA WA, 98402. The official website for the company is www.trueblue.com. The business services provider can be reached via phone at (253) 383-9101, via email at investorrelations@trueblueinc.com, or via fax at 877-733-0399.

This page (NYSE:TBI) was last updated on 3/24/2023 by MarketBeat.com Staff